Clinical Trial Update: CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial (CT-2103) evaluated CT-2103 in patients with recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CT-2103

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Fallopian Tube Cancer, Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED